Medical Licensing (MD/DO) · Independent exam preparation
FMCLA: Clinical Decisions for Continuing Family Medicine Certification Study Guide
Practise diagnostic choices, chronic treatment reviews, emergency responses and screening decisions through 60 focused concepts and 20 original FMCLA learning questions.
By CertMedbry · Updated 20 October 2026
Choose appropriate diagnostic tests, distinguish conditions needing antibiotics, review chronic treatment safely, recognize emergencies and apply screening criteria. This selective guide develops those decisions through 60 concepts, original cases and independent practice questions. The official ABFM clinical activity blueprint defines the full assessment scope, including disciplines and conditions beyond this sample.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide cover?
This guide covers the American Board of Family Medicine's Family Medicine Certification Longitudinal Assessment, or FMCLA, for continuing board certification. It is a physician board-certification assessment rather than a medical licensing examination. The 2026 booklet describes FMCLA within the continuing certification 5-Year Cycle.
ABFM — Longitudinal Assessment · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
How many questions are included, and how much time is available?
FMCLA comprises 300 questions, presented as a maximum of 25 questions per calendar quarter over three to four years. Once a question is opened, five minutes are available to review it and submit an answer. Quarterly questions may be completed together or across several sessions. There is no single sitting duration for the whole longitudinal assessment.
ABFM — Longitudinal Assessment · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
Which questions count toward scoring, and are there separate pretest items?
ABFM states that all 300 questions are scored; its cited materials identify no separate unscored pretest allotment. Viewed but unanswered questions count as incorrect. A shortfall from 300 answered questions at the end of four years also counts as incorrect. The minimum participation requirement of 275 answered questions is distinct from achieving the passing standard.
ABFM — Longitudinal Assessment · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
How is FMCLA delivered, and what item styles are verified?
Questions are delivered online through MyABFM Portfolio using a computer or other suitable device. The verified style is clinical scenarios with single-best-answer multiple-choice questions. Printed and electronic references are permitted, and immediate feedback follows submission. The cited ABFM materials do not establish computer-adaptive item selection. These 20 independent four-option drills provide practice with clinical reasoning and do not predict assessment success.
ABFM — Family Medicine Exam Blueprint · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
Which blueprint applies, and how is this guide distributed?
The clinical activity blueprint became effective in January 2025 and explicitly applies to FMCLA. The dedicated blueprint and 2026 handbook give Acute Care and Diagnosis 35%, Chronic Care Management 25%, Emergent and Urgent Care 20%, Preventive Care 15%, and Foundations of Care 5%. This guide allocates 21, 15, 12, 9 and 3 concepts respectively. The questions and flashcards each allocate 7, 5, 4, 3 and 1 items respectively. These proportions organize the sample; ABFM does not prescribe its selected subtopic counts.
ABFM — Family Medicine Exam Blueprint · ABFM — Developing the New Family Medicine Certification Scale Blueprint · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
Why do some ABFM overview percentages differ?
The longitudinal assessment overview's Knowledge Gap Report paragraph lists a conflicting distribution. This guide follows the dedicated official blueprint, corroborated by the 2026 handbook, rather than that paragraph. No additional numbered blueprint revision is established.
ABFM — Longitudinal Assessment · ABFM — Family Medicine Exam Blueprint · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
How does the one-day examination relate to FMCLA?
The Family Medicine Certification Exam, described as the one-day exam, is a separate assessment option for satisfying the continuing certification examination requirement. It shares the clinical activity blueprint but has different administration arrangements. The 2026 5-Year Cycle booklet makes that option available beginning in year four and identifies it as the examination pathway for certification re-entry; FMCLA is unavailable during re-entry.
ABFM — Family Medicine Exam Blueprint · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
How should feedback, scoring and reference use guide preparation?
ABFM provides immediate correctness feedback and a rationale. After submission, critique review is untimed, but the item, critique and references cannot be reopened after navigating away. An estimated scaled score becomes available in year two after at least 75 completed questions, with subsequent updates. Final scoring accounts for question difficulty and uses the same passing standard as the one-day exam. The cited materials do not specify a numerical cut score. Reference use must remain individual: assessment content cannot be reproduced, shared or entered verbatim into online tools.
ABFM — Longitudinal Assessment · ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
These independently authored learning materials support eligible family physicians preparing for ABFM continuing board certification. Clinical recommendations are supported by the cited clinical authorities; domain assignments follow the clinical activities described by ABFM. Gastrointestinal, musculoskeletal, vestibular and routine maternity topics are editorial selections within this broad scope. The selected subtopics are educational choices, not ABFM-mandated subtopic quotas.
Outline used: ABFM clinical activity blueprint effective January 2025, verified against the current official blueprint and the 2026 Family Medicine 5-Year Cycle Registration Information Booklet on 2026-10-10. The assigned workbook name matches the official assessment name. FMCLA fulfills a continuing board-certification examination requirement; the workbook category is an organizational classification rather than a description of a medical licensing examination.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Acute Care and Diagnosis35%
1.Which symptom trajectories support bacterial rhinosinusitis?
CDC describes three patterns: persistent symptoms beyond 10 days without improvement; severe illness with fever at least 39°C plus purulent nasal discharge or facial pain lasting more than three to four days; or worsening after initial improvement, such as new fever or increased discharge or cough after an initially improving viral illness. These trajectories are more discriminating than mucus color alone. A short illness that is steadily improving generally supports symptomatic care rather than antibiotics or routine sinus imaging.
Apply it
A teacher's nasal congestion improves after five days, then worsens with new fever and facial pain. Identify the second deterioration as a bacterial-pattern clue and assess severity, complications and suitability for treatment or observation.
Common pitfall: A brief fever or green discharge alone does not satisfy the severe bacterial pattern. Apply the temperature, associated symptoms and duration together.
2.Which presenting features and lung-function results support an asthma diagnosis?
Asthma requires typical variable respiratory symptoms plus evidence of variable expiratory airflow. In adults, a positive bronchodilator response is an increase in FEV1 or FVC of at least 12% and at least 200 mL from the pre-bronchodilator value. Both thresholds must be met. Initially normal spirometry or absent reversibility does not exclude asthma: repeat testing during symptoms or use another supported demonstration, such as excessive average daily peak-flow variability above 10% over two weeks or a positive bronchial challenge. Document objective evidence before controller treatment when feasible.
Apply it
An adult with intermittent nocturnal cough and exercise-associated wheeze has FEV1 increasing from 2.00 to 2.30 L after bronchodilator: a 15% and 300 mL increase, satisfying the adult criterion. If initial testing is normal between episodes, arrange repeat testing during symptoms or another appropriate variability assessment.
Common pitfall: A 12% increase of only 150 mL does not meet the adult spirometric criterion. Pediatric criteria differ; do not apply the adult percentage-and-volume rule indiscriminately to children.
GINA — 2026 Summary Guide for Asthma Management and Prevention
3.How should an acute cough be assessed for pneumonia?
In an otherwise healthy adult, acute bronchitis assessment first asks whether pneumonia is plausible. Fever, tachycardia, tachypnea or focal consolidation findings increase concern and may justify chest imaging. Normal vital signs and a nonfocal examination make pneumonia less likely in this population. Colored sputum does not establish bacterial infection. Once uncomplicated bronchitis is identified, routine antibiotics offer little value, even when cough persists longer than the patient expected.
Apply it
A healthy adult with cough has temperature 37.1°C, pulse 78, respiratory rate 16 and clear lungs. Explain why these findings support uncomplicated bronchitis, while giving return instructions for breathlessness, fever or clinical deterioration.
Common pitfall: Applying the reassuring normal-vitals rule indiscriminately to frail or medically complex patients overextends guidance framed around otherwise healthy adults with uncomplicated presentations.
CDC — Outpatient Clinical Care for Adults · CDC — Chest Cold (Acute Bronchitis) Basics
4.How does reduced need for sleep differ from ordinary insomnia?
In a manic presentation, a person may sleep very little yet feel unusually energetic rather than tired. Associated elevated or irritable mood, accelerated speech, racing thoughts, increased activity and risky behavior strengthen concern for a bipolar episode. Ordinary insomnia commonly leaves the person wanting sleep and feeling fatigued. Establish the change from baseline, duration, functional consequences, substance exposure and medication history. Psychosis or dangerous behavior requires urgent assessment rather than an isolated sleep prescription.
Apply it
A patient sleeping two hours nightly feels energized, speaks rapidly and has begun reckless spending. Assess the activated mood syndrome and immediate safety rather than treating the presentation as uncomplicated insomnia.
Common pitfall: Short sleep alone is insufficient to diagnose mania. The accompanying change in energy, mood, behavior and functioning supplies the discriminating evidence.
5.When does a sore throat need streptococcal testing?
Clear viral features such as cough, rhinorrhea, hoarseness, oral ulcers or conjunctivitis usually make group A streptococcal testing unnecessary. Without these features, examination alone cannot reliably distinguish viral from streptococcal pharyngitis. Testing then helps direct treatment rather than using exudate as proof of bacterial disease. The decision separates patients with a recognizable viral syndrome from those whose probability of streptococcal infection warrants microbiologic confirmation.
Apply it
A teenager has sore throat, conjunctivitis, hoarseness and a cough. Recognize the coherent viral pattern and provide supportive care rather than ordering a streptococcal test simply because the tonsils appear inflamed on examination.
Common pitfall: Tonsillar exudate is not specific enough to justify antibiotics by itself. Testing patients with obvious viral illness can also identify colonization rather than causation.
CDC — Clinical Guidance for Group A Streptococcal Pharyngitis
6.How does age change follow-up of a negative rapid strep test?
Rapid antigen tests are highly specific but can miss streptococcal infections. In symptomatic children aged three years or older, a negative rapid antigen test should be followed by throat culture, with a process for contacting the family and treating a positive result. Routine backup culture is generally unnecessary in adults because acute rheumatic fever is very rare. The same initial test result therefore leads to different next steps according to age.
Apply it
An eight-year-old with fever, tender anterior cervical nodes and no cough has a negative rapid antigen test. Send a throat culture and establish how the family will receive the result and any required treatment.
Common pitfall: Treating every negative result as definitive misses pediatric infections. Conversely, automatically culturing every adult negative result ignores the different risk underlying the recommendation.
CDC — Clinical Guidance for Group A Streptococcal Pharyngitis
7.How does CKD change initial treatment of an established acute gout flare?
For acute gout in CKD, KDIGO prefers low-dose colchicine or intra-articular or oral glucocorticoids over NSAIDs because of NSAID toxicity. Colchicine dosing requires particular review in CKD G5. Select anti-inflammatory treatment according to kidney function and the patient's circumstances.
Apply it
A patient with CKD and a confirmed gout flare requests ibuprofen. Consider low-dose colchicine or a glucocorticoid instead, reviewing kidney function before prescribing.
Common pitfall: A familiar gout treatment is not equally suitable at every level of kidney function.
KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
8.What otoscopic findings establish acute otitis media?
Acute otitis media requires middle-ear effusion plus appropriate acute inflammatory findings. Moderate or severe tympanic membrane bulging, or new otorrhea unrelated to otitis externa, strongly supports diagnosis. Mild bulging needs recent ear pain or marked erythema. Pneumatic otoscopy or tympanometry helps establish effusion. A red membrane alone is insufficient because redness does not demonstrate infected middle-ear fluid. Diagnostic certainty should precede the decision about antibiotics or observation.
Apply it
A crying toddler has a red but normally positioned tympanic membrane with preserved mobility. Reassess for effusion and other causes of discomfort rather than diagnosing acute otitis media solely from the color of the membrane.
Common pitfall: Ear tugging and erythema are suggestive symptoms, but neither substitutes for evidence of middle-ear effusion and the required tympanic membrane findings on examination.
9.When is observation appropriate for nonsevere acute otitis media?
Nonsevere disease means mild otalgia lasting less than 48 hours and temperature below 39°C. Assess otorrhea: acute otitis media with otorrhea generally warrants antibiotics rather than observation. Without otorrhea, observation may be considered for unilateral nonsevere disease at ages 6–23 months and unilateral or bilateral nonsevere disease at age 24 months or older. Provide pain relief and a mechanism for reassessment and starting antibiotics if symptoms worsen or fail to improve within 48–72 hours.
Apply it
A three-year-old has mild bilateral ear pain for one day, temperature 38°C, confirmed acute otitis media and no otorrhea. Discuss observation with analgesia and a clear 48–72-hour reassessment or antibiotic plan.
Common pitfall: Reliable follow-up alone does not establish eligibility. Age, laterality, otorrhea, pain intensity, pain duration and temperature determine whether observation is appropriate.
CDC — Outpatient Clinical Care for Pediatric Populations · AOM Symptom Severity and Treatment Options | eqipp.aap.org
10.Which urinary findings support a bladder-limited cystitis treatment pathway?
Dysuria, urgency, frequent small voids and suprapubic discomfort support cystitis. Before selecting bladder-directed treatment, assess fever, flank pain, costovertebral-angle tenderness and systemic illness, which suggest infection beyond the bladder. Suspected pyelonephritis requires urine culture, severity assessment and an antibiotic with appropriate renal-tissue exposure; nitrofurantoin and oral fosfomycin generally lack adequate renal-parenchymal or bloodstream levels. For healthy, nonpregnant, premenopausal adults with bladder-limited infection, CDC lists nitrofurantoin, fosfomycin and TMP-SMX when local resistance is below 20% as first-line options.
Apply it
A healthy nonpregnant adult has dysuria, urgency, suprapubic discomfort and positive nitrites, with no fever, flank pain, costovertebral-angle tenderness or systemic illness. Select an appropriate first-line cystitis agent after checking kidney function, allergies and local resistance.
Common pitfall: A positive urine dipstick does not distinguish cystitis from pyelonephritis. Pregnancy and signs of infection beyond the bladder change the evaluation and treatment pathway.
CDC — Outpatient Clinical Care for Adults · IDSA 2025 Guideline Update on Complicated Urinary Tract Infections · clinical-question-1-2025.pdf
11.How does typical infant bronchiolitis differ from an asthma treatment problem?
Bronchiolitis usually presents in children younger than 24 months with a viral prodrome followed by cough, wheeze and increased respiratory effort. Typical uncomplicated cases are diagnosed clinically and generally do not need routine laboratory testing or chest radiography. Supportive care, including nasal suctioning, is central. CDC does not recommend routine albuterol or corticosteroids for outpatient bronchiolitis. Wheezing alone does not establish the reversible asthma phenotype for which those therapies are used.
Apply it
An otherwise healthy nine-month-old develops rhinorrhea followed by a first wheezing illness, remains hydrated and has mild respiratory effort. Choose supportive care and reassessment instructions rather than automatically prescribing an asthma controller or bronchodilator.
Common pitfall: The shared symptom of wheeze can obscure different illnesses. A typical first infant bronchiolitis episode should not automatically receive the same medication plan as established asthma.
12.Which urine findings establish a urinary infection in a young child?
A reliable specimen is crucial when diagnosing urinary infection in a child aged 2–24 months. The cited CDC guidance combines a urinalysis suggesting infection with growth of at least 50,000 CFU/mL of one uropathogen from catheterized or suprapubic urine. Bag cultures are unsuitable for definitive diagnosis because contamination undermines interpretation. Negative nitrites do not exclude infection in children. Specimen quality and inflammatory findings must be interpreted together rather than accepting bacterial growth alone.
Apply it
A febrile 14-month-old has mixed bacterial growth from a bag specimen. Obtain an appropriately collected urine sample for urinalysis and culture rather than labeling the mixed growth as a confirmed urinary infection requiring treatment.
Common pitfall: A positive culture from a contaminated collection method can create a false diagnosis. Conversely, absent nitrites alone cannot safely rule out pediatric urinary infection.
13.Why should thyroid disease remain in the differential for mood symptoms?
Hypothyroidism can produce fatigue, slowed thinking and depressive symptoms. These complaints overlap with psychiatric presentations and are not diagnostic by themselves. A history of cold intolerance, constipation, thyroid disease or replacement therapy can increase the value of thyroid testing. NIMH also emphasizes evaluating medical conditions and substances that can resemble bipolar symptoms. Combine the physical history, medication review and indicated laboratory assessment with a longitudinal mood history rather than assuming that all symptoms have one psychiatric cause.
Apply it
A patient requesting treatment for low mood also reports new cold intolerance and constipation. Assess the mood history and obtain appropriate thyroid testing rather than selecting an antidepressant solely from the presenting complaint.
Common pitfall: An abnormal thyroid result does not automatically explain every mood symptom, just as a psychiatric history does not exclude a concurrent endocrine disorder.
American Thyroid Association — Hypothyroidism · NIMH — Bipolar Disorder
14.What findings distinguish symptomatic vulvovaginal candidiasis?
Vulvovaginal candidiasis causes symptoms such as vulvar itching, soreness and external dysuria, but those complaints are not specific. Budding yeast, hyphae or pseudohyphae on microscopy support the diagnosis in a symptomatic patient. Vaginal pH usually remains below 4.5. Potassium hydroxide preparation improves visualization by clearing obscuring cellular material. The combination of symptoms, normal-range vaginal pH and fungal elements is more discriminating than discharge appearance or itching considered alone.
Apply it
A patient has vulvar itching, curdy discharge, vaginal pH 4.2 and budding yeast on microscopy. Use the combined findings to identify symptomatic candidiasis and distinguish it from a vaginitis pattern dominated by elevated pH and odor.
Common pitfall: Itching does not uniquely identify candidiasis. Treating every pruritic discharge as yeast disease can delay identification of another infectious or noninfectious cause of symptoms.
15.Which abdominal-pain pattern supports irritable bowel syndrome, and which findings require another explanation?
An IBS pattern combines recurrent abdominal pain with at least two associations: defecation, altered stool frequency or altered stool form. Pain related to defecation may improve or worsen afterward. Symptoms occurring at least weekly during the past three months, with onset at least six months earlier, support the characteristic duration. Anemia, rectal bleeding, black stools or weight loss require evaluation for another cause. Review medications, examination and family history of celiac disease, inflammatory bowel disease or colorectal cancer when selecting further tests. See [NIDDK diagnostic guidance](https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/diagnosis).
Apply it
An adult reports eight months of weekly abdominal pain associated with defecation and changes in stool frequency and form. Assess for alarm findings and relevant family history before making a positive symptom-based diagnosis and selecting any additional testing.
Common pitfall: Bloating alone does not establish IBS. Bleeding, anemia or unexplained weight loss should not be attributed to IBS without investigating an alternative cause.
16.Which candidiasis treatment is appropriate during pregnancy?
Pregnancy changes the acceptable treatment for vulvovaginal candidiasis. CDC recommends topical azole therapy applied for seven days. Oral fluconazole should be avoided because epidemiologic studies associate even a single standard dose with spontaneous abortion and congenital anomalies. The practical decision is about route and duration, rather than simply choosing any medication active against Candida. Confirm the symptomatic diagnosis and pregnancy status before carrying over a familiar regimen from nonpregnant care.
Apply it
A pregnant patient with microscopy-confirmed candidiasis requests the single oral tablet she previously used. Explain the pregnancy-specific evidence and offer a seven-day topical azole course rather than repeating the prior oral treatment regimen.
Common pitfall: A convenient one-dose regimen outside pregnancy is not automatically suitable during pregnancy. Previous successful use does not remove the pregnancy-specific safety concern for oral fluconazole.
17.Which findings establish bacterial vaginosis, and how can symptomatic infection be treated during pregnancy?
Amsel diagnosis requires at least three of four findings: thin homogeneous discharge, clue cells, vaginal pH above 4.5 and a fishy odor before or after potassium hydroxide. Clue cells are epithelial cells coated with adherent bacteria. Treat symptomatic bacterial vaginosis during pregnancy; one accepted regimen is metronidazole 500 mg orally twice daily for seven days. Metronidazole is considered low risk during pregnancy. Avoid tinidazole during pregnancy, and avoid secnidazole because pregnancy efficacy and safety data are insufficient. Other accepted regimens exist, so the stated metronidazole course is one concrete option.
Apply it
A pregnant patient has bothersome thin discharge, pH 5.3, a positive whiff test and clue cells. Diagnose symptomatic bacterial vaginosis and, absent relevant allergy or intolerance, prescribe oral metronidazole 500 mg twice daily for seven days.
Common pitfall: Elevated pH alone does not diagnose bacterial vaginosis. Treating symptomatic infection differs from screening asymptomatic pregnant patients; pregnancy does not justify withholding all effective treatment.
18.When does an initial low-back-pain assessment warrant imaging?
Evaluate neurologic function and evidence of fracture, infection or malignancy before labeling acute low back pain uncomplicated. Routine imaging is discouraged when focal deficits and other warning findings are absent. Relevant clues include trauma or osteoporosis, fever with infection risk, previous cancer and unexplained weight loss. New urinary retention, saddle sensory loss or severe progressive weakness raises concern for cauda equina compression and requires emergency evaluation rather than routine imaging follow-up. See the [VA/DoD low-back-pain guideline](https://www.healthquality.va.gov/guidelines/Pain/lbp/VADoDLBPCPGFinal508.pdf).
Apply it
An adult develops localized back pain after lifting, with a normal neurologic examination and no trauma, fever, cancer history or bladder symptoms. Explain why immediate imaging is unnecessary and give specific instructions to return for new neurologic or systemic findings.
Common pitfall: The recommendation against routine imaging applies after a targeted history and examination. It does not justify overlooking serious or progressive neurologic deficits.
19.Why can early Lyme serology be negative despite infection?
Lyme antibody tests depend on an immune response that takes time to develop. During the first weeks of infection, especially around the appearance of erythema migrans, insufficient antibodies can produce a false-negative result. Assessment therefore incorporates exposure likelihood, timing, compatible manifestations and alternative diagnoses. A negative early result has a different meaning from a negative result after an adequate antibody-development interval. It should not override a strongly compatible early clinical presentation.
Apply it
After hiking in an endemic area, a patient develops an expanding rash and has negative antibody testing early in the illness. Interpret the result in relation to timing rather than using it to dismiss the compatible presentation.
Common pitfall: Treating an antibody test as direct detection of the organism ignores the early window period. Diagnostic confidence depends on when testing occurs relative to infection.
20.How should triggered positional vertigo be distinguished from other dizziness presentations?
Distinct vertigo spells triggered by changes in head position suggest benign paroxysmal positional vertigo (BPPV). Diagnose posterior-canal BPPV when the Dix–Hallpike maneuver provokes vertigo with torsional, upbeating nystagmus. If the history is compatible but Dix–Hallpike testing produces horizontal or no nystagmus, perform a supine roll test to assess for horizontal-canal BPPV. Treat confirmed posterior-canal disease with a canalith repositioning procedure. Routine imaging and routine vestibular suppressant treatment are discouraged when diagnostic criteria are met and no inconsistent findings are present. These clinical recommendations come from the [AAO-HNS BPPV guidance](https://www.entnet.org/resource/aao-hnsf-updated-cpg-bppv-press-release-fact-sheet/).
Apply it
A patient develops separate spinning spells when rolling in bed. Torsional, upbeating nystagmus during Dix–Hallpike testing supports posterior-canal BPPV and directs treatment toward canalith repositioning. Horizontal nystagmus instead calls for supine roll testing before selecting treatment. This topic samples ambulatory diagnosis; the official ABFM blueprint defines the full assessment scope of which this selective guide covers only a portion.
Common pitfall: Head-motion intolerance alone does not establish BPPV. Distinguish discrete position-triggered spells from continuous dizziness aggravated by movement. Persistent symptoms after treatment require reassessment for unresolved BPPV or another peripheral vestibular or central disorder; repeatedly prescribing meclizine does not substitute for confirming the positional diagnosis.
21.Which thyroid tests distinguish primary hypothyroidism from a central problem?
Primary hypothyroidism means the thyroid produces insufficient hormone despite pituitary stimulation. Low free T4 with elevated TSH supports that pattern because the pituitary increases its signal when thyroid output falls. Pituitary disease can disrupt this response, making TSH alone misleading. Symptoms such as fatigue, constipation and cold intolerance are suggestive but nonspecific. Interpret free T4 and TSH together when the clinical history raises concern about a central cause.
Apply it
A patient with fatigue and cold intolerance has low free T4 and markedly elevated TSH. Recognize primary thyroid failure. In a patient with pituitary disease, avoid excluding hypothyroidism merely because TSH is not elevated.
Common pitfall: A TSH value within its reference range is not universally reassuring when pituitary function is abnormal. The feedback pathway must be intact for usual interpretation.
Chronic Care Management25%
22.What establishes chronic kidney disease rather than a single abnormal result?
Chronic kidney disease requires abnormalities of kidney structure or function present for at least three months with implications for health. Persistently reduced eGFR below 60 mL/min/1.73 m² or persistent markers such as albuminuria can establish it. One abnormal result may instead reflect an acute process. Review prior measurements, urine findings and imaging, then repeat testing as appropriate. Chronicity is an evidentiary requirement, rather than an assumption attached to an isolated laboratory flag.
Apply it
A patient has eGFR 52 during a dehydrating illness and no previous results. Evaluate the acute context and obtain follow-up measurements rather than immediately assigning a permanent chronic kidney disease diagnosis from that single value.
Common pitfall: Waiting to establish chronicity does not mean ignoring possible acute kidney injury. Immediate evaluation and longitudinal diagnostic confirmation answer different clinical questions for the patient.
KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
23.How does CGA classification improve kidney risk assessment?
KDIGO classifies chronic kidney disease by cause, GFR category and albuminuria category, abbreviated CGA. eGFR describes filtration, while albuminuria adds information about kidney damage and prognosis. Albuminuria categories are A1 below 30 mg/g, A2 at 30–300 mg/g and A3 above 300 mg/g. Patients with identical filtration categories can have substantially different risks because their albuminuria or underlying disease differs. Recording all three dimensions supports more informative management than a stage number alone.
Apply it
Two patients have stable eGFR 48, but their urine ACR values are 12 and 450 mg/g. Classify both as G3a while distinguishing A1 from A3, and recognize why their risk discussions should differ.
Common pitfall: Calling both patients simply stage 3 conceals clinically important variation. A normal-looking creatinine or identical eGFR does not make albuminuria irrelevant to prognosis.
KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
24.How should empagliflozin be managed around elective surgery or prolonged fasting?
Withhold empagliflozin for at least three days before surgery or procedures involving prolonged fasting when possible. Its prescribing information specifies restarting when the patient is clinically stable and oral intake has resumed. If ketoacidosis occurred, confirm resolution before restarting. Advance planning matters because glucosuria and ketosis risk can persist after discontinuation. Incorporate the hold and restart criteria into the longitudinal medication plan and communicate them to the patient and surgical team.
Apply it
At a preoperative visit one week before elective surgery, schedule an empagliflozin hold beginning at least three days before the procedure. Specify postoperative stability and resumed oral intake as restart criteria.
Common pitfall: Waiting until fasting begins is not the labeled elective-surgery plan. A routine restart date without checking stability, intake and any ketoacidosis can also be unsafe.
204629s063lbl.pdf · KDIGO — Executive Summary of the 2024 CKD Guideline
25.How should recurrent hypoglycemia change a longitudinal diabetes plan?
Repeated lows require review of the treatment regimen and daily circumstances rather than repeated rescue treatment alone. Examine insulin or secretagogue dosing, missed meals, activity, alcohol use and changes in health or kidney function. Adjust the contributing treatment or meal-and-activity plan and ensure access to rapid carbohydrate. Patients at risk of severe episodes also need prescribed glucagon and trained caregivers. When empagliflozin is added to insulin or a sulfonylurea, its label advises considering a reduction in the insulin or secretagogue dose to reduce hypoglycemia risk.
Apply it
A patient reports repeated afternoon lows after becoming more active while continuing the same insulin and meal schedule. Review the pattern and adjust the plan instead of recommending extra snacks indefinitely without examining the cause.
Common pitfall: An acceptable average glucose does not make recurrent hypoglycemia safe. Review the distribution and timing of low values, not only an overall measure.
NIDDK — Low Blood Glucose (Hypoglycemia) · 204629s063lbl.pdf
26.When does a creatinine rise after an ACE inhibitor require reassessment?
Check blood pressure, creatinine and potassium within two to four weeks after starting or increasing an ACE inhibitor or ARB. A modest creatinine increase can occur during treatment and does not automatically require stopping it. KDIGO advises continuing unless creatinine rises by more than 30% within four weeks, while also considering symptomatic hypotension or uncontrolled hyperkalemia. The percentage change, timing and patient's clinical condition discriminate expected tolerance from a result requiring investigation and adjustment.
Apply it
Creatinine rises from 1.0 to 1.2 mg/dL after an ARB increase, with stable blood pressure and normal potassium. Calculate a 20% rise and continue planned review rather than stopping solely because the result increased.
Common pitfall: The 30% criterion does not override symptomatic hypotension or dangerous potassium elevation. A tolerable creatinine change must still be interpreted with the other safety findings.
27.Which patients qualify for SGLT2 kidney or heart-failure protection?
KDIGO recommends an SGLT2 inhibitor for type 2 diabetes with CKD and eGFR at least 20 mL/min/1.73 m². It also recommends treatment for adults with CKD, eGFR at least 20 and urine ACR at least 200 mg/g, or heart failure irrespective of albuminuria. Diabetes is not required for every indication. Empagliflozin's labeled adult heart-failure dose is 10 mg daily; 25 mg is an option for additional glycemic control. Assess renal function and correct volume depletion before initiation. At eGFR below 30, its reduced glucose-lowering effectiveness must be distinguished from an organ-protection indication.
Apply it
A patient without diabetes has CKD, eGFR 38 and persistent ACR 360 mg/g. Recognize a kidney-protection indication and discuss suitability rather than excluding treatment because glucose measurements are normal.
Common pitfall: Name the treatment goal. Eligibility for kidney or heart-failure protection does not establish adequate treatment of hyperglycemia, and higher dosing is not the labeled heart-failure strategy.
KDIGO — Executive Summary of the 2024 CKD Guideline · 204629s063lbl.pdf
28.How should levothyroxine be adjusted when pregnancy is confirmed in patients treated for overt versus subclinical hypothyroidism?
Obtain thyroid testing promptly when pregnancy is confirmed. For patients treated for overt hypothyroidism, an early levothyroxine increase of approximately 25% commonly addresses increased requirements, but individualize this using the preconception TSH and existing dose. A standardized increase carries greater overtreatment risk when preconception TSH is below 1.5 mU/L or the dose exceeds 100 micrograms/day. For patients treated for subclinical hypothyroidism, evidence does not support routinely applying the same 25% increase. The writing group's clinical experience supports either a small increase, such as 12.5 micrograms/day, or adjustment guided by testing every four weeks; these alternatives are not established as superior by comparative trials. The governing source for these distinctions is the [2026 ATA guideline](https://journals.sagepub.com/doi/pdf/10.1177/10507256261445624). The older ATA pregnancy brochure supports testing approximately every four weeks during the first half of pregnancy and separating levothyroxine from prenatal iron or calcium by at least four hours because these supplements impair absorption.
Apply it
For treated overt hypothyroidism with a preconception TSH of 2.0 mU/L on 100 micrograms/day, increasing initially to 125 micrograms/day is reasonable, followed by laboratory-guided adjustment. For preconception subclinical hypothyroidism treated with 50 micrograms/day, a small increase to 62.5 micrograms/day or testing-guided adjustment illustrates the writing group's experience-based options.
Common pitfall: Do not infer the original disease severity from the current normal TSH: treatment may have normalized either overt or subclinical hypothyroidism. Establish the original indication before choosing a pregnancy dose strategy. A low preconception TSH on a higher dose warrants particular attention to overtreatment, while simultaneous prenatal iron or calcium can create apparent underreplacement through reduced absorption.
Hypothyroidism in Pregnancy | American Thyroid Association · Thyroid Health – Management of Hypothyroidism During Pregnancy: When and how to treat? | American Thyroid Association
29.Why should adult asthma treatment contain an inhaled corticosteroid?
Asthma includes airway inflammation even when symptoms are infrequent. A short-acting bronchodilator relieves constriction but does not adequately address that inflammatory risk. GINA recommends ICS-containing treatment and discourages SABA-only management because severe exacerbations can occur despite apparently mild symptoms. For appropriate adults and adolescents, as-needed low-dose ICS-formoterol is a preferred initial strategy in relevant treatment steps. Choose the regimen by age, symptom pattern and available formulation while retaining an anti-inflammatory component.
Apply it
An adult with confirmed asthma uses albuterol only a few times monthly and requests another rescue inhaler. Discuss an ICS-containing strategy because infrequent symptoms do not eliminate the risk of a severe asthma exacerbation.
Common pitfall: Rapid symptom relief can make bronchodilator-only care seem sufficient. The missing element is prevention of inflammation-related exacerbation risk, which symptom frequency alone does not capture.
GINA — 2026 Summary Guide for Asthma Management and Prevention
30.What should be checked before stepping up asthma medication?
Persistent asthma symptoms do not always mean the prescribed drug intensity is inadequate. Before escalating, assess inhaler technique, adherence, relevant exposures, comorbidities and diagnostic accuracy. Poor delivery or irregular use can make an effective regimen appear unsuccessful. Watching the patient use the actual device often identifies a correctable cause. Escalation becomes more rational after these factors have been addressed and the remaining pattern supports insufficient control despite appropriate use of the current treatment.
Apply it
A patient remains symptomatic on a prescribed controller but demonstrates an ineffective inhalation technique. Correct the technique, confirm understanding and arrange reassessment before concluding that the medication dose has failed and requires immediate escalation.
Common pitfall: Increasing a prescribed dose cannot reliably compensate for medication that never reaches the airways. A prescription record also does not establish regular, correct use.
GINA — 2026 Summary Guide for Asthma Management and Prevention
31.How do asthma symptom control and future risk differ?
Current symptom control describes recent daytime symptoms, night waking, activity limitation and reliever needs. Future risk includes the possibility of exacerbations and adverse outcomes, which may remain elevated even when recent symptoms are limited. Previous severe attacks, excessive SABA use and inadequate ICS exposure are relevant warning clues. Assess both dimensions during review. A patient who feels comfortable today may still need treatment improvement because the longitudinal pattern shows preventable risk.
Apply it
A patient reports few recent symptoms but has required repeated rescue-inhaler refills and previously needed emergency treatment. Review future risk and anti-inflammatory treatment rather than classifying the asthma as safe solely from today's symptom report.
Common pitfall: A reassuring visit captures only one time point. Low current symptom burden does not negate a history or medication pattern indicating substantial future exacerbation risk.
GINA — 2026 Summary Guide for Asthma Management and Prevention
32.Which longitudinal clues distinguish bipolar depression from unipolar depression?
A depressive presentation requires a history extending beyond the current low mood. Previous periods of unusually increased energy, reduced need for sleep, elevated or irritable mood and consequential behavior suggest a bipolar course. Family history, medication effects and substance use add context. NIMH emphasizes reviewing the illness over time because a single episode can conceal the diagnosis. Establishing the pattern matters before treatment selection, particularly when considering an antidepressant without mood-stabilizing therapy.
Apply it
A patient seeking treatment for depression recalls a prior week of minimal sleep, expansive plans and uncontrolled spending that led to hospitalization. Explore the episode and longitudinal course before treating the current symptoms as uncomplicated unipolar depression.
Common pitfall: Focusing exclusively on today's depression can miss past mania. Reduced need for sleep with increased energy differs from insomnia accompanied by fatigue and distress.
33.Why is antidepressant monotherapy problematic in bipolar disorder?
In bipolar disorder, antidepressants used alone can precipitate mania or rapid cycling. Treatment commonly uses a mood stabilizer or an atypical antipsychotic, with selection depending on the current episode and longer-term needs. An antidepressant may sometimes be added within an appropriate treatment plan, but it should not be assumed to function like routine unipolar depression treatment. Review prior activation, episode history and existing therapy before making a medication change.
Apply it
A patient with established bipolar disorder asks to stop the mood stabilizer and continue only an antidepressant after feeling less depressed. Explain the destabilization risk and review an appropriate longitudinal treatment plan before changing either medication.
Common pitfall: Improvement in depressive symptoms does not establish that antidepressant monotherapy is safe. The treatment must also account for manic switching and the broader illness course.
34.How does long-term gout prevention differ from treating a flare in CKD?
Urate-lowering treatment addresses recurrent crystal-related disease rather than merely suppressing acute inflammation. KDIGO recommends offering it for CKD with symptomatic hyperuricemia and favors xanthine oxidase inhibitors over uricosurics. Xanthine oxidase inhibitors reduce uric acid production; uricosurics increase urinary excretion but become less effective with reduced GFR. Consider treatment even after a first gout episode in CKD, particularly with no avoidable precipitant or serum urate above 9 mg/dL. Do not prescribe urate lowering solely to slow CKD progression in asymptomatic hyperuricemia.
Apply it
A patient with CKD and recurrent established gout has been receiving only episodic anti-inflammatory treatment. Discuss long-term urate lowering, explaining the different preventive goal and the possibility of early flares when treatment begins.
Common pitfall: An elevated urate concentration without gout symptoms is a different treatment decision. Acute pain relief does not itself provide long-term control of urate deposition.
KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
35.When should thyroid function be reassessed after a dose change?
After starting or changing thyroid hormone replacement, the American Thyroid Association describes blood testing at approximately six to eight weeks. This allows time for the biochemical response to reflect the new regimen rather than reacting to an early transitional result. Symptoms remain relevant but are not sufficiently specific to direct repeated rapid adjustments alone. Pregnancy and interacting medications may require closer assessment. Match the monitoring interval to the clinical situation and the treatment change.
Apply it
A nonpregnant adult changed levothyroxine dose ten days ago and still feels tired. Review concerning symptoms and adherence, but plan routine biochemical reassessment at the appropriate interval rather than escalating again solely because fatigue persists today.
Common pitfall: Repeated changes before the prior adjustment can be meaningfully assessed make interpretation difficult. Persistent fatigue also does not prove inadequate thyroid replacement without appropriate biochemical assessment.
36.How should persistent reflux symptoms change an established GERD treatment plan?
Review symptom response and the treatment being used. Antacids relieve mild symptoms; H2 blockers reduce acid production, while PPIs generally provide stronger symptom control and esophageal healing. Weight reduction when indicated, smoking cessation and elevation of the upper body during sleep can help. Persistent symptoms despite medicines and lifestyle measures warrant reassessment and possible testing rather than indefinite self-treatment. Dysphagia, gastrointestinal bleeding or unexplained weight loss requires evaluation for complications or another disease. See [NIDDK treatment](https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/treatment), [diagnosis](https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/diagnosis) and [warning symptoms](https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults/symptoms-causes).
Apply it
A patient with established GERD needs antacids every day despite lifestyle measures. Review the regimen and discuss acid-suppressive treatment; new swallowing difficulty changes the task to investigating a possible complication rather than simply adding more antacid.
Common pitfall: Temporary symptom relief does not establish adequate management. Persistent or changing symptoms should prompt a review of the diagnosis and the need for investigation.
Treatment for GER & GERD - NIDDK · Diagnosis of GER & GERD - NIDDK · Symptoms & Causes of GER & GERD - NIDDK
Emergent and Urgent Care20%
37.Which findings identify anaphylaxis even without hives?
Anaphylaxis is a rapidly developing systemic allergic reaction that can compromise breathing or circulation. Wheeze, throat swelling, stridor, hypotension or collapse after a likely exposure are urgent clues. Skin findings are common but can be absent, so waiting for hives is unsafe when respiratory or cardiovascular compromise is present. Recognition is clinical and treatment should begin immediately with intramuscular epinephrine. The important distinction is systemic danger rather than the intensity of a visible local skin reaction.
Apply it
Minutes after vaccination, a patient develops throat tightness, wheezing and hypotension without a rash. Recognize anaphylaxis and give intramuscular epinephrine while activating emergency support.
Common pitfall: Absence of urticaria does not exclude anaphylaxis. A narrow focus on rash can delay treatment of a reaction already threatening the airway or circulation.
38.How should epinephrine be administered for adult anaphylaxis?
Give epinephrine 0.3–0.5 mg from the 1 mg/mL preparation intramuscularly into the mid-outer thigh for an adult with anaphylaxis. Repeat every 5–15 minutes as needed for persistent or recurrent symptoms while emergency support is arranged. This adult example is separate from pediatric weight-based dosing. Support airway and oxygenation; persistent hypotension also requires recumbent positioning when tolerated, intravenous isotonic fluid and continued reassessment. Antihistamines and inhaled bronchodilators are adjuncts and must not delay epinephrine.
Apply it
An adult develops hives, wheeze and hypotension after an injection. Give 0.3–0.5 mg intramuscular epinephrine using the 1 mg/mL preparation, record the time and reassess for repeat dosing within 5–15 minutes.
Common pitfall: Check the dose, concentration and route together. Improvement in itching after an antihistamine does not establish correction of respiratory or circulatory compromise.
39.Which perineal findings require urgent surgical assessment during SGLT2 treatment?
Pain or tenderness, erythema or swelling in the genital or perineal region accompanied by fever or malaise requires immediate evaluation for necrotizing fasciitis of the perineum, also called Fournier's gangrene. Empagliflozin prescribing information describes this as a life-threatening infection requiring urgent surgical intervention. If suspected, discontinue empagliflozin, begin prompt broad-spectrum antibiotic treatment and obtain urgent surgical assessment for debridement when needed. Do not manage systemic illness and perineal inflammation as an uncomplicated superficial fungal infection.
Apply it
A patient taking empagliflozin develops painful perineal swelling with fever and malaise. Arrange immediate hospital and surgical evaluation, stop the drug and initiate treatment for possible necrotizing infection.
Common pitfall: The familiar association between SGLT2 inhibitors and genital candidiasis can distract from a surgical emergency. Systemic illness with painful perineal inflammation requires a different response.
40.Why can postoperative ketoacidosis occur without marked hyperglycemia?
Surgery, reduced caloric intake, volume depletion and insufficient insulin can precipitate ketoacidosis during SGLT2 treatment. Empagliflozin-associated ketoacidosis may present with glucose below 250 mg/dL. Nausea, vomiting, abdominal pain, malaise or shortness of breath in this setting requires assessment for ketosis and metabolic acidosis regardless of glucose level. Stop empagliflozin if ketoacidosis is suspected, evaluate promptly and treat confirmed ketoacidosis. Drug-related glucosuria and ketosis risk can persist after discontinuation.
Apply it
After surgery and poor intake, a patient recently taking empagliflozin develops vomiting and breathlessness with glucose 180 mg/dL. Obtain urgent ketone and acid-base assessment rather than dismissing ketoacidosis because glucose is below its usual range.
Common pitfall: A recent drug hold does not eliminate the diagnosis. Do not use a modest glucose concentration as a rule-out test for ketoacidosis in an exposed patient.
41.Which features should trigger treatment for suspected opioid overdose?
Opioid overdose should be considered when a person cannot be awakened and has slow, shallow or absent breathing, sometimes with pinpoint pupils or discolored lips. Noisy gurgling or snoring in an unresponsive person is not reassuring sleep. Give naloxone when available and obtain emergency assistance while supporting breathing. A history of stimulant use does not exclude opioid exposure because other drugs can contain fentanyl. The immediate decision rests on the dangerous clinical pattern.
Apply it
A bystander finds an unresponsive person with very slow breathing after reported cocaine use. Treat possible opioid contamination with naloxone and emergency assistance rather than dismissing opioid overdose because the reported drug was a stimulant.
Common pitfall: Waiting for certainty about the ingested substance delays lifesaving treatment. The combination of unresponsiveness and respiratory depression is more useful than an incomplete exposure history.
42.What should happen when breathing remains abnormal after naloxone?
Naloxone is one component of overdose response, rather than a replacement for emergency care. CDC advises giving an initial dose and assessing whether normal breathing returns within two to three minutes before giving another dose when needed. Continue emergency assistance, breathing support as appropriate and observation until responders arrive. A partial awakening is less important than adequate ventilation. Clinical response guides the next action, and the person should not be left alone after apparent improvement.
Apply it
Two to three minutes after nasal naloxone, a patient remains barely responsive with slow breathing. Give another dose according to the product instructions while emergency help and breathing support continue, rather than waiting indefinitely for full awakening.
Common pitfall: Opening the eyes is not the only treatment target. Persistently inadequate breathing remains an emergency even if consciousness improves slightly after the first naloxone dose.
43.Which symptom combinations raise concern for myocardial infarction?
Possible myocardial infarction can present with central pressure, squeezing or fullness, discomfort in the arms, jaw, back or stomach, breathlessness, sweating, nausea or lightheadedness. Symptoms may begin mildly, fluctuate or occur without prominent chest discomfort. Women commonly have chest discomfort too, although other associated symptoms can be prominent. Recognize the combination and context rather than demanding a stereotyped severe crushing pain before acting. Warning symptoms warrant immediate emergency assessment.
Apply it
An older adult reports new exertional upper-body discomfort, nausea and breathlessness that recur after briefly easing. Treat the cluster as possible myocardial ischemia and obtain emergency assistance rather than assuming improvement excludes a serious cardiac problem.
Common pitfall: Symptoms that fluctuate or feel like indigestion can still represent infarction. Requiring dramatic continuous chest pain sets an unsafe threshold for recognizing a cardiac emergency.
American Heart Association — Warning Signs of a Heart Attack
44.Why should suspected infarction prompt EMS activation?
Suspected myocardial infarction requires rapid access to assessment and treatment. Calling emergency medical services allows trained responders to begin care, manage sudden deterioration and arrange timely transport. The patient should not wait for an office appointment or drive independently simply because symptoms are currently tolerable. The decision is based on credible warning signs rather than diagnostic certainty. EMS activation moves evaluation and support into the interval that would otherwise be spent waiting or traveling without assistance.
Apply it
A patient phones about new central pressure with sweating and asks whether to drive to tomorrow's appointment. Direct immediate EMS activation because the symptoms could represent infarction and deterioration can occur before a scheduled assessment.
Common pitfall: A plan to seek care eventually is inadequate for suspected infarction. Independent transport also forfeits the opportunity for trained responders to provide care during deterioration.
American Heart Association — Warning Signs of a Heart Attack
45.How should an alert adult treat symptomatic hypoglycemia?
An alert adult who can swallow safely should treat low glucose promptly with 15–20 grams of glucose or rapidly available carbohydrate. NIDDK recommends rechecking after 15 minutes and repeating treatment if glucose remains low. If the next meal is more than an hour away, a snack can help maintain recovery. The process includes confirmation of response rather than assuming one intake has corrected the episode. Choice of treatment must account for consciousness and swallowing safety.
Apply it
An insulin-treated adult is shaky, alert and able to swallow, with glucose 58 mg/dL. Give measured rapid carbohydrate, recheck after 15 minutes and repeat if needed rather than simply advising the patient to eat later.
Common pitfall: Treating symptoms without rechecking can miss persistent hypoglycemia. Oral carbohydrate also becomes unsafe when consciousness or swallowing is impaired, even if it worked previously.
46.Which response is appropriate when hypoglycemia prevents self-treatment?
Severe hypoglycemia can impair consciousness, cause seizures and prevent safe self-treatment. In the community, glucagon supplied as an injection or nasal product can raise glucose when oral intake is unsafe. Caregivers should know where it is and how to use it, and emergency help is still needed. Do not place food or liquid into the mouth of an unconscious person. The decisive distinction from a mild episode is inability to treat safely without another person's assistance.
Apply it
A partner finds an insulin-treated patient unconscious and has a prescribed glucagon device available. Use the device and summon emergency help rather than trying to pour juice into the patient's mouth while waiting for recovery.
Common pitfall: The usual oral carbohydrate approach cannot be transferred to an unconscious patient. Aspiration risk changes the treatment route and makes prepared caregiver action especially important.
47.How should life-threatening acute asthma be stabilized during transfer?
Drowsiness, confusion or a silent chest during an asthma attack indicates life-threatening deterioration and requires immediate transfer with intensive-care escalation. Begin inhaled SABA, inhaled ipratropium, controlled oxygen and systemic corticosteroids concurrently while arranging transfer; do not postpone treatment for routine investigations. For adults and adolescents, GINA targets oxygen saturation of 92–95%. A quiet chest may reflect critically reduced airflow rather than improvement. Follow mental status, air entry, respiratory effort and oxygenation, and avoid sedatives.
Apply it
A patient becomes drowsy with minimal air entry after previously wheezing loudly. Continue immediate bronchodilator treatment, add ipratropium, give oxygen and systemic corticosteroids, and activate intensive emergency transfer.
Common pitfall: Quieter wheezing is not reassuring when air entry and consciousness deteriorate. Transfer arrangements and stabilization must proceed together.
GINA — 2026 Summary Guide for Asthma Management and Prevention
48.Which potassium result requires immediate action rather than routine follow-up?
KDIGO identifies potassium at least 6.5 mmol/L as severe hyperkalemia requiring immediate assessment and treatment, including blood testing and ECG monitoring. At 6.0–6.4 mmol/L, an acutely unwell patient or one with AKI needs hospital assessment; an unexpected result in a clinically well patient requires repeat testing within 24 hours.
Apply it
A laboratory reports potassium 6.7 mmol/L in a patient with CKD. Arrange immediate emergency assessment and ECG monitoring.
Common pitfall: Do not substitute a future medication review or dietary advice for immediate action on severe hyperkalemia.
KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Preventive Care15%
49.When should average-risk colorectal screening begin?
The USPSTF recommends colorectal cancer screening beginning at age 45 for asymptomatic average-risk adults and continuing routinely through age 75. Its 2021 recommendation distinguishes this preventive pathway from evaluation of symptoms and from surveillance for established high-risk conditions. A patient with rectal bleeding or a relevant previous diagnosis needs an appropriately directed assessment rather than simply being assigned an average-risk screening schedule. Establish eligibility and clinical purpose before choosing the test.
Apply it
An asymptomatic 46-year-old without prior polyps, inflammatory bowel disease or a known hereditary syndrome has never been screened. Offer an appropriate screening strategy now rather than waiting until age 50 under an older starting-age recommendation.
Common pitfall: Screening ages apply to preventive care in the defined population. They should not be used to postpone diagnostic assessment of concerning symptoms in a younger patient.
50.How should colorectal screening methods be matched to patient circumstances?
Colorectal screening offers several supported strategies with different burdens and intervals. Annual FIT can be completed at home, whereas screening colonoscopy is generally repeated every 10 years after an appropriate normal examination. Other accepted methods have their own schedules. Selection should consider willingness, preparation, sedation, transport and capacity to complete follow-up. A convenient initial test is useful only if the patient can sustain the recommended schedule and undergo diagnostic evaluation when an abnormal result occurs.
Apply it
A patient declines screening colonoscopy because of preparation and transport concerns but would complete a home test. Discuss annual FIT and explain the need for colonoscopy after a positive result before agreeing on the strategy.
Common pitfall: Offering a stool test as a way to avoid colonoscopy under all circumstances is misleading. Abnormal stool screening still requires the appropriate diagnostic follow-up.
51.What is the next step after a positive stool screening test?
A positive stool-based colorectal screening test requires colonoscopy to obtain the benefit of the screening strategy. Repeating the stool test does not resolve the original abnormal result because bleeding and marker detection can vary between samples. The positive result changes the task from routine screening to diagnostic follow-up. Explain that the result does not itself diagnose cancer, but it does require evaluation rather than reassurance based on absence of symptoms or a subsequent negative sample.
Apply it
An asymptomatic adult has a positive FIT and asks to repeat it because hemorrhoids seem a likely explanation. Arrange colonoscopy and explain why a possible benign source does not eliminate the need to evaluate the abnormal screen.
Common pitfall: A second negative stool test cannot erase the first positive result. Using repeat sampling as reassurance can interrupt the screening pathway before diagnostic evaluation occurs.
52.How should colorectal screening be individualized after age 75?
For adults aged 76–85, USPSTF recommends selective colorectal screening based on health, prior screening and preferences. Previously unscreened healthy adults may have more opportunity to benefit than patients with adequate prior screening and substantial competing illness. Procedure-related burdens and harms also matter. Screening should stop after age 85 under this recommendation. The decision therefore requires more than chronological age: it asks whether detecting disease is likely to improve this patient's meaningful future outcomes.
Apply it
Two 79-year-olds request screening: one is healthy and never screened, while the other has major illness and repeated adequate prior screening. Use the different histories to discuss likely benefit and burden rather than offering identical recommendations.
Common pitfall: Neither automatic continuation nor automatic refusal captures the recommendation for ages 76–85. Prior screening and overall health materially change the balance for an individual patient.
53.Which smoking history qualifies for USPSTF lung screening?
The USPSTF 2021 recommendation supports annual low-dose CT for adults aged 50–80 with at least 20 pack-years who currently smoke or quit within the past 15 years. Calculate pack-years by multiplying average packs per day by years, adding periods when exposure changed. Eligibility requires the combination of age, cumulative exposure and cessation timing. Screening concerns asymptomatic patients; symptoms suggesting lung cancer require diagnostic assessment rather than simply enrollment in routine screening.
Apply it
A 58-year-old smoked half a pack daily for 24 years and one pack daily for 12 years, quitting four years ago. Calculate 24 pack-years and recognize eligibility for discussion of annual low-dose CT screening.
Common pitfall: Counting smoking years alone overestimates or underestimates exposure. A long history at low intensity must be converted to pack-years before applying the threshold accurately.
54.When should lung screening stop, and how does cessation fit?
USPSTF lung screening should stop after 15 years without smoking or when health substantially limits life expectancy or the ability or willingness to undergo curative lung surgery. These boundaries reflect the need for detection to lead to meaningful treatment benefit. Current smokers should also receive cessation interventions because CT does not prevent tobacco-related disease. Screening and cessation address different goals and should be discussed together rather than allowing one to substitute for the other.
Apply it
A patient meeting the smoking exposure threshold develops illness that precludes curative lung surgery. Reconsider continued screening through shared decision-making rather than ordering the next annual scan solely because the patient remains within the age range.
Common pitfall: Eligibility is not permanent once established. Changes in cessation duration, health and treatment willingness can change the balance even when past scans were appropriate screening.
55.Which adults fall within the USPSTF osteoporosis screening recommendation?
The January 2025 USPSTF recommendation supports osteoporosis screening in women aged 65 or older and in younger postmenopausal women at increased risk. DXA, with or without fracture risk assessment as appropriate, identifies patients who may benefit from treatment. The recommendation concerns adults without known osteoporosis or a history requiring a different management pathway. Evidence is insufficient to determine the balance of routine screening in men. Insufficient evidence is distinct from proof that screening cannot benefit an individual.
Apply it
A healthy 67-year-old woman without previous fragility fracture asks whether bone testing is appropriate. Offer osteoporosis screening under the age-based recommendation rather than requiring additional risk factors before considering an initial DXA assessment for her.
Common pitfall: An insufficient-evidence statement for men is not a prohibition. It also does not justify extending the women's age-based recommendation to every man without individual assessment.
56.How can a named risk tool guide osteoporosis screening below age 65?
For younger postmenopausal women, first identify additional risk factors such as low body weight, parental hip fracture, smoking or excess alcohol use. Then use a clinical risk tool. The Osteoporosis Self-assessment Tool, OST, is calculated as 0.2 × (weight in kilograms − age in years). A score below 2 is a commonly used tool-specific threshold indicating increased osteoporosis risk and supporting DXA screening. ORAI uses a different commonly used threshold of at least 9. USPSTF does not specify a universal FRAX threshold for deciding whom to screen.
Apply it
A 58-year-old postmenopausal woman weighs 50 kg and has a parental hip-fracture history. Her OST is 0.2 × (50 − 58) = −1.6. This is below 2 and supports proceeding to DXA after discussing the screening decision.
Common pitfall: OST estimates osteoporosis risk; it does not diagnose osteoporosis. Do not transfer its threshold to FRAX or confuse fracture-treatment thresholds with a universal USPSTF screening cutoff.
57.Which urine screening belongs in routine early prenatal care?
USPSTF recommends screening pregnant patients for asymptomatic bacteriuria with a midstream clean-catch urine culture at the first prenatal visit or at 12–16 weeks, whichever is earlier. Culture detects bacteriuria despite absent urinary symptoms; dipstick testing alone is not the recommended screening method. Identifying and treating significant bacteriuria reduces pyelonephritis risk during pregnancy. Routine screening is generally performed once; evidence about optimal repeat-screening frequency is limited. This recommendation differs from the recommendation against routine screening in nonpregnant adults. See [USPSTF prenatal screening guidance](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/asymptomatic-bacteriuria-in-adults-screening).
Apply it
An asymptomatic patient attends a first prenatal visit at 10 weeks. Obtain a screening urine culture now rather than waiting for dysuria or substituting a negative office dipstick.
Common pitfall: Absence of symptoms does not remove the indication for prenatal screening. Conversely, screening asymptomatic nonpregnant adults is a different preventive decision.
Foundations of Care5%
58.How do absolute risk reduction and NNT clarify treatment benefit?
Absolute risk reduction is the comparator event risk minus the treatment event risk. Relative risk reduction divides that difference by comparator risk, while NNT is the reciprocal of the absolute difference expressed as a proportion. Always specify the outcome, comparator and follow-up period. These measures describe different aspects of the same evidence: a large relative reduction can correspond to a small absolute benefit when baseline risk is low. NNT represents an expected average, rather than a guaranteed outcome for each group.
Apply it
In an invented four-year trial, events occur in 12% receiving usual care and 9% receiving treatment. Calculate a three-percentage-point absolute reduction, 25% relative reduction and an NNT rounded upward to 34 over four years.
Common pitfall: Using three instead of 0.03 in the reciprocal produces the wrong NNT. Omitting the timeframe also makes comparisons between different studies potentially misleading to readers.
Cochrane Handbook — Chapter 15: Interpreting Results and Drawing Conclusions
59.What does informed vaccine discussion require in United States practice?
CDC describes culturally sensitive, understandable discussion of vaccine benefits and risks, with an opportunity for questions. Under the National Childhood Vaccine Injury Act, vaccine information statements must be provided whenever a vaccine covered by the Act is administered. The Act does not itself require a signed consent form, although state or local requirements may differ. Document informed refusal when vaccination is declined. Legal compliance and meaningful understanding are related responsibilities, rather than interchangeable paperwork tasks.
Apply it
A parent receives a vaccine information statement but still has questions about adverse reactions. Address the concerns in understandable language and document the discussion rather than treating delivery of the handout as completion of informed communication.
Common pitfall: Do not infer a universal federal signature requirement from the VIS requirement. Equally, providing the document does not replace answering questions or checking understanding.
60.How can kidney care address inequity without race-based eGFR adjustment?
KDIGO advises avoiding race in eGFR computation and recognizes disparities in access to kidney care. Use appropriate validated estimation methods while addressing practical barriers to testing, medication and follow-up. An identical prescription does not ensure an equal opportunity to benefit when cost, transportation or service availability differ. Ask what prevents implementation and coordinate feasible care. The clinical task combines accurate assessment with attention to access rather than using a racial category as a substitute for individual physiology.
Apply it
A patient repeatedly misses kidney monitoring because transport is unavailable. Arrange a feasible laboratory plan and review medication access, while using an appropriate race-free eGFR approach rather than attributing missed care to lack of interest alone.
Common pitfall: Removing race from an equation does not by itself remove barriers to care. Equity also requires attention to whether recommended testing and treatment can actually occur.
KDIGO — Executive Summary of the 2024 CKD Guideline · KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Identify the clinical activity before solving the case: initial diagnosis, longitudinal management, a decision needed within hours, prevention or an evidence-and-systems issue.
- Prioritize discriminating cues: illness trajectory, age, pregnancy, specimen quality, medication exposure, chronicity and ability to swallow or breathe safely.
- Practise distinct decisions across respiratory, endocrine, mental-health, pediatric, musculoskeletal, skin, urinary, cardiovascular, kidney and surgical care. Include abdominal-pain patterns, reflux treatment, positional vertigo, low-back assessment and routine prenatal screening.
- Apply named screening recommendations precisely, including eligibility, tool-specific risk thresholds, stopping criteria and completion of diagnostic follow-up.
- Use the full official outline to review disciplines and conditions beyond this selective sample, including surgical patient care, maternity care, children, older adults and community medicine.
A practical preparation plan
1. Organize study by clinical activity
Allocate review approximately 35% acute diagnosis, 25% chronic management, 20% emergent and urgent care, 15% prevention and 5% foundations. Within each domain, identify unfamiliar patient groups and disciplines using the official outline.
2. State the discriminator before choosing
For each practice case, name the finding that changes the decision: a second deterioration, a child's negative rapid antigen test, unsafe swallowing, persistent albuminuria or a positive screening result.
3. Review chronic care as a sequence
Link each treatment to its indication, baseline assessment, monitoring interval, expected changes and reasons to interrupt or escalate. Practise this sequence for kidney protection, diabetes, asthma, gout, reflux and thyroid replacement, including pregnancy and elective perioperative planning.
4. Make emergency actions explicit
State the medication, route and timing when relevant, which measures must occur together and what requires transfer or continued observation. Rehearse anaphylaxis, overdose, hypoglycemia, suspected infarction, severe asthma, severe hyperkalemia and surgical emergencies.
5. Use references with a focused question
Practise locating a specific diagnostic criterion, treatment recommendation or monitoring threshold efficiently, then applying it to the patient's age, presentation, comorbidities and treatment goal.
6. Convert errors into targeted review
After these independent drills, explain why each alternative fails and create a brief recall question around the missed distinction. Track gaps by clinical activity and discipline, then review conditions beyond this selective sample.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABFM — Longitudinal Assessment
- ABFM — Family Medicine Exam Blueprint
- ABFM — 2026 Family Medicine 5-Year Cycle Registration Information Booklet
- ABFM — Developing the New Family Medicine Certification Scale Blueprint
- CDC — Outpatient Clinical Care for Adults
- CDC — Chest Cold (Acute Bronchitis) Basics
- CDC — Clinical Guidance for Group A Streptococcal Pharyngitis
- CDC — Outpatient Clinical Care for Pediatric Populations
- CDC — Vulvovaginal Candidiasis
- CDC — Bacterial Vaginosis
- CDC — Testing and Diagnosis for Lyme Disease
- KDIGO — 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- KDIGO — Executive Summary of the 2024 CKD Guideline
- GINA — 2026 Summary Guide for Asthma Management and Prevention
- NIMH — Bipolar Disorder
- American Thyroid Association — Hypothyroidism
- CDC — Preventing and Managing Adverse Reactions
- CDC — 5 Things to Know About Naloxone
- American Heart Association — Warning Signs of a Heart Attack
- NIDDK — Low Blood Glucose (Hypoglycemia)
- USPSTF — Colorectal Cancer: Screening
- USPSTF — Lung Cancer: Screening
- USPSTF — Osteoporosis to Prevent Fractures: Screening
- Cochrane Handbook — Chapter 15: Interpreting Results and Drawing Conclusions
- 204629s063lbl.pdf
- 2026-Registration-Information-Booklet-Family-Medicine-5-Year-Cycle.pdf
- AOM Symptom Severity and Treatment Options | eqipp.aap.org
- Hypothyroidism in Pregnancy | American Thyroid Association
- Thyroid Health – Management of Hypothyroidism During Pregnancy: When and how to treat? | American Thyroid Association
- IDSA 2025 Guideline Update on Complicated Urinary Tract Infections
- clinical-question-1-2025.pdf
- Recommendation: Asymptomatic Bacteriuria in Adults: Screening | United States Preventive Services Taskforce
- Diagnosis of Irritable Bowel Syndrome - NIDDK
- Treatment for GER & GERD - NIDDK
- Diagnosis of GER & GERD - NIDDK
- Symptoms & Causes of GER & GERD - NIDDK
- VADoDLBPCPGFinal508.pdf
- IDSA 2014 Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.